Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Moreno Obregón

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Medicina Clinica|June 12, 2018
Clinical interview and mobile phoneFernando Moreno Obregón, David León Jiménez, Miguel Pedregal González
Journal of Cellular Physiology|January 31, 2019
In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways"David León Jiménez, Fernando Moreno Obregón, José Pablo Miramontes González
Atencion Primaria|July 22, 2019
[Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation]Fernando Moreno Obregón, Antonio Espino Montoro, Jorge Marín Martín, et al.
Atencion Primaria|September 5, 2017
[Digoxin: Does it have a rest at weekends?]Ana Pareja-Obregón Prieto, Fernando Moreno Obregón, David León Jiménez, et al.
Reumatologia Clinica|December 20, 2017
RS3PE syndrome with positive rheumatoid factorFernando Moreno Obregón, Matilde Del Castillo Madrigal, Fernando Díaz Narváez, et al.
Kidney International|January 6, 2020
Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?David León-Jiménez, Fernando Moreno-Obregón, Luis M Beltrán-Romero, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 27, 2021
Basal insulin analogues in people with diabetes and chronic kidney diseaseDavid León-Jiménez, José Pablo Miramontes-González, Laura Márquez-López, et al.
Diabetes Research and Clinical Practice|November 5, 2019
Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 monthsFernando Moreno Obregón, José Pablo Miramontes-González, Catalina Romo Guajardo-Fajardo, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Medicina Clinica|June 12, 2018
Clinical interview and mobile phoneFernando Moreno Obregón, David León Jiménez, Miguel Pedregal González
Journal of Cellular Physiology|January 31, 2019
In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways"David León Jiménez, Fernando Moreno Obregón, José Pablo Miramontes González
Atencion Primaria|July 22, 2019
[Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation]Fernando Moreno Obregón, Antonio Espino Montoro, Jorge Marín Martín, et al.
Atencion Primaria|September 5, 2017
[Digoxin: Does it have a rest at weekends?]Ana Pareja-Obregón Prieto, Fernando Moreno Obregón, David León Jiménez, et al.
Reumatologia Clinica|December 20, 2017
RS3PE syndrome with positive rheumatoid factorFernando Moreno Obregón, Matilde Del Castillo Madrigal, Fernando Díaz Narváez, et al.
Kidney International|January 6, 2020
Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?David León-Jiménez, Fernando Moreno-Obregón, Luis M Beltrán-Romero, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 27, 2021
Basal insulin analogues in people with diabetes and chronic kidney diseaseDavid León-Jiménez, José Pablo Miramontes-González, Laura Márquez-López, et al.
Diabetes Research and Clinical Practice|November 5, 2019
Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 monthsFernando Moreno Obregón, José Pablo Miramontes-González, Catalina Romo Guajardo-Fajardo, et al.
Pageof 1